Viridian Therapeutics, Inc. (VRDN)
Oxford Ledge is still expanding full research coverage of VRDN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biopharmaceutical company developing medicines for serious autoimmune and rare diseases with lead candidates for thyroid eye disease.
SEC filings
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-29
- 8-K Shareholder vote results 2026-06-03
- 8-K Termination of material agreement 2026-05-28
- 8-K Entry into material agreement 2026-05-26
- 8-K Entry into material agreement; Creation of direct financial obligation; Other material event; Financial statements and exhibits 2026-05-11
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for VRDN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open VRDN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.